Features
- In vitro electrophysiology for diabetes research
- MEA-based parallelized screening system for intact islets of Langerhans
- Two configurations for either long-term, incubator-ready chronic or non-invasive acute recordings
Technology
Microelectrode array (MEA) based non-invasive screening
Utilizing the MEA technology allows parallelized recording of beta cell activity of intact islets of Langerhans. Simple handling and higher throughput as in intracellular recordings or patch-clamp comply with academic and industrial needs. As market leader in MEA technology we offer systems for acute and chronic recordings matching your research needs.
Application
Explore new possibilities in drug discovery and diabetes reseach
The MEA technology opens new routes to support the development of new drugs for the treatment of type 2 diabetes mellitus, as well as to elucidate beta cell pathophysiology e.g. during the progression of diabetes. It allows the analysis of isolated human islets, fraction of plateau phase (FOPP) as marker for insulin release, and the investigation of pathophysiological reactions like oxidative stress.
News Update
Article About New Routes for Type 2 Diabetes Drug Development on RDmag.com
Read the article "Beta Cell-System Offers New Route for Type 2 Diabetes Drug Development" about the possibility of long term measurements from intact islet cells thanks to the non-invasive MEA technology.
Interview About the Beta-Screen System on Technology Networks
Read the whole interview "Improving Preclinical Diabetes Research" with Dr. Sven Schönecker about the possibilities of non-invasive electrophysiological recordings from intact islets of Langerhans with the Beta-Screen system.